Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 5/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | HTR7 | P34969 | 5/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30484353 | 1.00 | CHRM4 (0.39) | CHRM4DRD2HTR7CYP19A1HTR2A | |
| SCHEMBL22852087 | 0.92 | CHRM4 (0.37) | CHRM4DRD2HTR7CYP19A1HTR2C | |
| SCHEMBL10286027 | 0.84 | CHRM4 (0.39) | CHRM4DRD2HTR7CYP19A1HTR2A | |
| SCHEMBL10286040 | 0.83 | HDAC1 (0.42) | CHRM4DRD2HTR7CYP19A1HTR2A | |
| SCHEMBL14885005 | 0.83 | HDAC1 (0.42) | CHRM4DRD2HTR7CYP19A1HTR2A | |
| SCHEMBL30694265 | 0.83 | HDAC1 (0.42) | CHRM4DRD2HTR7CYP19A1HTR2A | |
| SCHEMBL10286793 | 0.81 | CHRM4 (0.38) | CHRM4DRD2HTR7CYP19A1 | |
| SCHEMBL10286028 | 0.79 | CHRM4 (0.41) | CHRM4DRD2HTR7HTR2AHTR2C | |
| SCHEMBL14885003 | 0.79 | CHRM4 (0.41) | CHRM4DRD2HTR7HTR2AHTR2C | |
| SCHEMBL4066821 | 0.78 | HTR2A (0.32) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112142748-B | Pyrazolopyrimidine compound, and preparation method and application thereof | 上海医药集团股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20220324868-A1 | Pyrazolone-Fused Pyrimidine Compound, and Preparation Method and Use Therefor | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2022-10-13 | — | — | US | disclosed |
| EP-4008719-A2 | PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2022-06-08 | — | — | EP | disclosed |
| EP-4008719-A2 | PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2022-06-08 | — | — | EP | disclosed |
| WO-2020259724-A2 | PYRAZOLONE AND PYRIMIDINE COMPOUND, AND PREPARATION METHOD AND USE THEREFOR | 上海医药集团股份有限公司 | 2020-12-30 | — | — | WO | disclosed |
| CN-112142748-A | Pyrazolone pyrimidine compound, preparation method and application thereof | 上海医药集团股份有限公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-105884752-B | And ring class gyrase and topoisomerase I V inhibitor | 山东轩竹医药科技有限公司 | 2018-08-31 | — | — | CN | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324868-A1 | Pyrazolone-Fused Pyrimidine Compound, and Preparation Method and Use Therefor | WEE1, WEE2, WASF2 | CHRM4 4809/4885DRD2 4557/4885HTR7 2317/4885 |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | CHRM4 299/4885DRD2 149/4885HTR7 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.